AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 163 filers reported holding AGIOS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $572,121 | -33.0% | 23,116 | -23.3% | 0.03% | -30.4% |
| Q2 2023 | $853,678 | -3.5% | 30,144 | -21.8% | 0.05% | -16.4% |
| Q1 2023 | $884,896 | +262.7% | 38,524 | +360.2% | 0.06% | +450.0% |
| Q1 2022 | $244,000 | -20.3% | 8,372 | -10.0% | 0.01% | 0.0% |
| Q4 2021 | $306,000 | -41.3% | 9,307 | -17.6% | 0.01% | -44.4% |
| Q3 2021 | $521,000 | -10.2% | 11,289 | +7.2% | 0.02% | -5.3% |
| Q2 2021 | $580,000 | +10.3% | 10,533 | +3.5% | 0.02% | -5.0% |
| Q1 2021 | $526,000 | +3.5% | 10,177 | -13.1% | 0.02% | -9.1% |
| Q4 2020 | $508,000 | +36.2% | 11,713 | +9.8% | 0.02% | +15.8% |
| Q3 2020 | $373,000 | -48.1% | 10,665 | -20.6% | 0.02% | -52.5% |
| Q2 2020 | $718,000 | +82.2% | 13,434 | +21.0% | 0.04% | +33.3% |
| Q1 2020 | $394,000 | -45.5% | 11,099 | -26.7% | 0.03% | -3.2% |
| Q4 2019 | $723,000 | +87.3% | 15,148 | +27.3% | 0.03% | +55.0% |
| Q3 2019 | $386,000 | -38.5% | 11,899 | -5.4% | 0.02% | -33.3% |
| Q2 2019 | $628,000 | -34.2% | 12,583 | -11.1% | 0.03% | -34.8% |
| Q1 2019 | $955,000 | +49.0% | 14,155 | +1.9% | 0.05% | +15.0% |
| Q4 2018 | $641,000 | -51.8% | 13,891 | -19.4% | 0.04% | -20.0% |
| Q3 2018 | $1,330,000 | +2.6% | 17,241 | +12.0% | 0.05% | -3.8% |
| Q2 2018 | $1,296,000 | -0.2% | 15,388 | -3.1% | 0.05% | 0.0% |
| Q1 2018 | $1,298,000 | +49.2% | 15,875 | +4.3% | 0.05% | +52.9% |
| Q4 2017 | $870,000 | -24.1% | 15,226 | -11.4% | 0.03% | -29.2% |
| Q3 2017 | $1,147,000 | +39.5% | 17,182 | +7.6% | 0.05% | +29.7% |
| Q2 2017 | $822,000 | +5.0% | 15,971 | +19.1% | 0.04% | +5.7% |
| Q1 2017 | $783,000 | +29.9% | 13,413 | -7.1% | 0.04% | +25.0% |
| Q4 2016 | $603,000 | -31.2% | 14,443 | -12.9% | 0.03% | -33.3% |
| Q3 2016 | $876,000 | +45.5% | 16,580 | +15.3% | 0.04% | +44.8% |
| Q2 2016 | $602,000 | -0.2% | 14,381 | -3.2% | 0.03% | -6.5% |
| Q1 2016 | $603,000 | -49.8% | 14,860 | -19.6% | 0.03% | -45.6% |
| Q4 2015 | $1,200,000 | -7.9% | 18,491 | +0.2% | 0.06% | -23.0% |
| Q3 2015 | $1,303,000 | – | 18,454 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rock Springs Capital Management LP | 2,661,605 | $61,137,067 | 1.46% |
| Bellevue Group AG | 4,013,500 | $92,190,095 | 1.34% |
| Eagle Health Investments LP | 267,630 | $6,147,461 | 1.20% |
| ARMISTICE CAPITAL, LLC | 3,460,000 | $79,476,200 | 1.14% |
| Integral Health Asset Management, LLC | 213,000 | $4,892,610 | 0.99% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 454,000 | $10,428,380 | 0.44% |
| ArrowMark Colorado Holdings LLC | 1,557,705 | $35,780,484 | 0.41% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,092,829 | $48,072,282 | 0.27% |
| Virtus ETF Advisers LLC | 9,932 | $228,138 | 0.13% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 614,533 | $14,115,823 | 0.09% |